Abstract

Myasthenia gravis (MG) is an autoimmune disorder caused by a decrease in functional acetylcholine receptors at the neuromuscular junction resulting from their destruction or inactivation by antibodies. Patients with MG can experience marked sensitivity to nondepolarizing neuromuscular blocking agents (NMBAs), and require specialized anesthetic care because of their increased risk of postoperative weakness and respiratory failure. Since pyridostigmine, a cholinesterase inhibitor, is a mainstay of MG treatment, the conventional neostigmine antagonism is unfavorable. Sugammadex is a direct, selective antagonist of aminosteroid NMBAs. It is a cyclodextrin derivative that irreversibly encapsulates rocuronium or vecuronium to terminate its action at the nicotinic receptor. Sugammadex is not reliant on acetylcholinesterase or any receptor system and appears to be capable of antagonizing profound neuromuscular blockade (NMB).

Author Details

Presley Harrison, DNP (c), RN

Sigma Membership

Non-member

Lead Author Affiliation

Samford University, Birmingham, Alabama, USA

Type

DNP Capstone Project

Format Type

Text-based Document

Study Design/Type

N/A

Research Approach

N/A

Keywords:

Myasthenia Gravis, Sugammadex, Residual Neuromuscular Blockade

Advisor

Herbinger, Lisa

Second Advisor

Greenway, Mary Beth

Degree

DNP

Degree Grantor

Samford University

Degree Year

2021

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Review Type

None: Degree-based Submission

Acquisition

Proxy-submission

Date of Issue

2021-03-24

Full Text of Presentation

wf_yes

Download

Additional Files

download (58 kB)

Share

COinS